NZ783532A - Compositions and methods for the treatment of hemoglobinopathies - Google Patents

Compositions and methods for the treatment of hemoglobinopathies

Info

Publication number
NZ783532A
NZ783532A NZ783532A NZ78353216A NZ783532A NZ 783532 A NZ783532 A NZ 783532A NZ 783532 A NZ783532 A NZ 783532A NZ 78353216 A NZ78353216 A NZ 78353216A NZ 783532 A NZ783532 A NZ 783532A
Authority
NZ
New Zealand
Prior art keywords
cell
nucleic acid
grna molecule
molecule
seq
Prior art date
Application number
NZ783532A
Other versions
NZ783532B2 (en
Inventor
Yi Yang
Anthony Edward Boitano
Michael Cooke
Lloyd B Klickstein
Reynald Lescarbeau
Craig Stephen Mickanin
Kabungo Mulumba
Seshidhar Reddy Police
Jennifer Snead
Susan C Stevenson
Morag Stewart
Original Assignee
Novartis Ag
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Intellia Therapeutics Inc filed Critical Novartis Ag
Publication of NZ783532A publication Critical patent/NZ783532A/en
Publication of NZ783532B2 publication Critical patent/NZ783532B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides gRNA molecules targeting BCL11A, compositions, cells, and methods of preparing said gRNA molecules and cells for the treatment of hemoglobinopathies. In a particular embodiment, the gRNA molecule comprises a tracr and crRNA, wherein the crRNA comprises a targeting domain comprising CUAACAGUUGCUUUUAUCAC (SEQ ID NO: 253), and the tracr comprises GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU (SEQ ID NO: 7811).

Claims (25)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. A gRNA molecule comprising a crRNA and a sequence set forth in SEQ ID NO: 7811, wherein the crRNA comprises a targeting domain comprising SEQ ID NO:
2. The gRNA molecule of claim 1, wherein the gRNA molecule comprises: (a) one or more phosphorothioate modifications at the 3’ end of said gRNA molecule; (b) one or more phosphorothioate modifications at the 5’ end of gRNA molecule; (c) one or more 2’-O-methyl modifications at the 3’ end of said gRNA molecule; (d) one or more 2’-O-methyl modifications at the 5’ end of said gRNA molecule; th rd (e) a 2’ O-methyl modification at each of the 4 -to-terminal, 3 -to-terminal, and 2 -to-terminal 3’ residues of said gRNA molecule; th rd (f) a 2’ O-methyl modification at each of the 4 -to-terminal, 3 -to-terminal, and 2 -to-terminal 5’ residues of said gRNA molecule; or (g) any combination thereof.
3. A composition comprising: (a) the gRNA molecule of claim 1 or claim 2 and a Cas9 molecule; (b) the gRNA molecule of claim 1 or claim 2 and a nucleic acid encoding a Cas9 molecule; (c) a nucleic acid encoding the gRNA molecule of claim 1 or claim 2 and a Cas9 molecule; (d) a nucleic acid encoding the gRNA molecule of claim 1 or claim 2 and a nucleic acid encoding a Cas9 molecule; (e) any of (a) to (d) above, and a template nucleic acid; or (f) any of (a) to (d) above, and a nucleic acid comprising sequence encoding a template nucleic acid.
4. A composition comprising the gRNA molecule of any one of claim 1 or claim 2, further comprising a Cas9 molecule, wherein the Cas9 molecule is an active or inactive S. pyogenes Cas9.
5. The composition of claim 4, wherein the Cas9 molecule comprises any one of SEQ ID NO: 6611, SEQ ID NO: 7821, SEQ ID NO: 7822, SEQ ID NO: 7823, SEQ ID NO: 7824, SEQ ID NO: 7825, SEQ ID NO: 7826, SEQ ID NO: 7827, SEQ ID NO: 7828, SEQ ID NO: 7829, SEQ ID NO: 7830, or SEQ ID NO: 7831.
6. The composition of claim 4, wherein the gRNA molecule and Cas9 molecule are present in a ribonuclear protein complex (RNP).
7. The composition of claim 3, formulated in a medium suitable for electroporation.
8. A nucleic acid that encodes the gRNA molecule of claim 1 or claim 2.
9. A vector comprising the nucleic acid of claim 8.
10. An ex-vivo method of altering an isolated cell at or near a target sequence within said cell, comprising contacting said cell with: (a) the gRNA molecule of claim 1 or claim 2 and a Cas9 molecule; (b) the gRNA molecule of claim 1 or claim 2 and a nucleic acid encoding a Cas9 molecule; (c) a nucleic acid encoding the gRNA molecule of claim 1 or claim 2 and a Cas9 molecule; (d) a nucleic acid encoding the gRNA molecule of claim 1 or claim 2 and a nucleic acid encoding a Cas9 molecule; (e) any one of (a) to (d) above, and a template nucleic acid; (f) any one of (a) to (d) above, and a nucleic acid encoding a template nucleic acid; (g) the composition of claim 3; or (h) the vector of claim 9.
11. The ex-vivo method of claim 10, wherein the isolated cell is a CD34+ cell.
12. The ex-vivo method of claim 10, wherein: (a) the altering results in an indel at or near a genomic DNA sequence complementary to the targeting domain of the gRNA molecule; (b) the method results in a population of cells wherein at least 50% of the cells of the population have been altered; (c) the altering results in a cell that is capable of differentiating into a differentiated cell of an erythroid lineage, wherein said differentiated cell exhibits an increased level of fetal hemoglobin relative to an unaltered cell; (d) the altering results in a population of cells that is capable of differentiating into a population of differentiated cells, wherein said population of differentiated cells has an increased fraction of F cells relative to a population of unaltered cells; or (e) the altering results in a cell that is capable of differentiating into a differentiated cell, wherein said differentiated cell produces at least 6 picograms fetal hemoglobin per cell.
13. An isolated cell comprising the gRNA molecule of claim 1 or claim 2, the composition of claim 3, the nucleic acid of claim 8, or the vector of claim 9.
14. The isolated cell of claim 13, further comprising a template nucleic acid.
15. The isolated cell of claim 13, further comprising a Cas9 molecule.
16. The isolated cell of claim 13, wherein: (a) the expression of fetal hemoglobin is increased in said cell or its progeny relative to a cell or its progeny of the same cell type that has not been modified to comprise the gRNA molecule; or (b) the cell is capable of differentiating into a differentiated cell, wherein said differentiated cell exhibits an increased level of fetal hemoglobin relative to a cell of the same type that has not been modified to comprise the gRNA molecule.
17. The isolated cell of claim 13, wherein the cell is a CD34+ cell.
18. A population of isolated cells comprising the isolated cell of any one of claims 13-17, wherein at least 50% of the cells of the population are an isolated cell according to claim 13-17.
19. An ex-vivo method of preparing a cell comprising: (a) providing an isolated cell; (b) culturing said cell ex vivo in a cell culture medium comprising a stem cell expander; and (c) introducing into said cell the gRNA molecule of claim 1 or claim 2, a nucleic acid molecule encoding the gRNA molecule of claim 1 or claim 2, the composition of claim 3, the nucleic acid of claim 8, or the vector of claim 9.
20. The ex-vivo method of claim 19, wherein the stem cell expander is: (1r,4r)-N -(2-benzyl(2-methyl-2H-tetrazolyl)-9H-pyrimido[4,5-b]indol yl)cyclohexane-1,4-diamine; methyl 4-(3-piperidinylpropylamino)-9H-pyrimido[4,5-b]indolecarboxylate; 4-(2-(2-(benzo[b]thiophenyl)isopropyl-9H-purinylamino)ethyl)phenol; (S)(6-(2-(lH-indolyl)ethylamino)(5-fluoropyridinyl)-9H-purin yl)propan-l-ol; or a combination thereof.
21. The ex-vivo method of claim 19, wherein the introducing of step (c) comprises an electroporation.
22. A pharmaceutical composition comprising the gRNA molecule of claim 1 or claim 2, the composition of claim 3, the nucleic acid of claim 8, the vector of claim 9, the isolated cell of any one of claims 13-17, or the population of isolated cells of claim
23. Use of a pharmaceutical composition comprising the gRNA molecule of claim 1 or claim 2, the composition of claim 3, the nucleic acid of claim 8, the vector of claim 9, the isolated cell of any one of claims 13-17, or the population of isolated cells of claim 18, in the manufacture of a medicament for the treatment of a hemoglobinopathy.
24. The use of claim 23, wherein the pharmaceutical composition comprises a pharmaceutically acceptable medium.
25. The use of claim 23, wherein the hemoglobinopathy is sickle cell disease or beta- thalassemia.
NZ783532A 2016-12-26 Compositions and methods for the treatment of hemoglobinopathies NZ783532B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271968P 2015-12-28 2015-12-28
US201662347484P 2016-06-08 2016-06-08
NZ744649A NZ744649A (en) 2015-12-28 2016-12-26 Compositions and methods for the treatment of hemoglobinopathies

Publications (2)

Publication Number Publication Date
NZ783532A true NZ783532A (en) 2025-09-26
NZ783532B2 NZ783532B2 (en) 2026-01-06

Family

ID=

Also Published As

Publication number Publication date
IL308706A (en) 2024-01-01
US20190010495A1 (en) 2019-01-10
NZ783534A (en) 2025-09-26
MX2018007987A (en) 2019-01-10
KR20250141840A (en) 2025-09-29
KR102860636B1 (en) 2025-09-17
AU2020223733A1 (en) 2020-09-17
CA3009727A1 (en) 2017-07-06
NZ744649A (en) 2025-09-26
US20240002843A1 (en) 2024-01-04
IL260257A (en) 2018-07-31
JP2021166514A (en) 2021-10-21
JP2019500043A (en) 2019-01-10
SG11201805217XA (en) 2018-07-30
JP7844400B2 (en) 2026-04-13
EA201891532A1 (en) 2019-01-31
HK1258205A1 (en) 2019-11-08
IL260257B1 (en) 2024-01-01
MY192848A (en) 2022-09-12
EP4053277A1 (en) 2022-09-07
BR112018013065A2 (en) 2018-12-11
MX2022009148A (en) 2022-08-16
CN108779462A (en) 2018-11-09
KR20180103923A (en) 2018-09-19
WO2017115268A1 (en) 2017-07-06
RU2018127636A3 (en) 2020-10-23
NZ783531A (en) 2025-09-26
IL260257B2 (en) 2024-05-01
AU2016381313B2 (en) 2020-11-26
EP3397767A1 (en) 2018-11-07
AU2025200366A1 (en) 2025-04-10
RU2018127636A (en) 2020-02-03
PH12018501378A1 (en) 2019-04-08
AU2020223733B2 (en) 2022-01-27
JP2026126208A (en) 2026-08-04
AU2016381313A1 (en) 2018-07-12
AU2022202558A1 (en) 2022-05-12
JP2023159185A (en) 2023-10-31
JP7851081B2 (en) 2026-04-24

Similar Documents

Publication Publication Date Title
GB2556276A (en) Engineered crispr-CAS9 compositions and methods of use
WO2017053431A3 (en) Allele selective gene editing and uses thereof
CN109312315A (en) Carrier-Free Delivery of Gene Editing Proteins and Compositions to Cells and Tissues
Hecox-Lea et al. Evolutionary diversity and novelty of DNA repair genes in asexual Bdelloid rotifers
US20250263752A1 (en) Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
Rajamani et al. Genetic and epigenetic instability of stem cells
Shi et al. Synaptic plasticity of human umbilical cord mesenchymal stem cell differentiating into neuron‐like cells in vitro induced by edaravone
Kaminski et al. Engineering kidney cells: reprogramming and directed differentiation to renal tissues
Rudnitsky et al. Mesenchymal stem cells and their derivatives as potential longevity-promoting tools
Somorjai et al. Stem cells: a view from the roots
NZ783531A (en) Compositions and methods for the treatment of hemoglobinopathies
NZ783532B2 (en) Compositions and methods for the treatment of hemoglobinopathies
NZ783531B2 (en) Compositions and methods for the treatment of hemoglobinopathies
WO2007089950A3 (en) Preparations of growth hormone
Finotti et al. Ground state naïve pluripotent stem cells and CRISPR/Cas9 gene correction for β-thalassemia
Brändl et al. Stem cell reprogramming: basic implications and future perspective for movement disorders
KR20190069238A (en) Keap1 Knock-out human embryonic stem cell and method of manufacturing the cell
EP3901252A1 (en) Composition for removing pluripotent stem cells and method of removing pluripotent stem cells
Bellayr et al. 245. MicroRNA Expression in Bone Marrow-Derived Human MSCs
Patel et al. 244. Development and Qualification of Assays for Human Embryonic Stem Cell (hESC)-Derived Cardiomyocytes Intended for Clinical Use
CN121729252A (en) Methods and compositions for engineered DA neuronal cells
Christensen et al. Adult Stem Cells
Cheng et al. Stem cell epigenetics in medical therapy
Chen et al. CURRENT ADVANCES
Karthikeyan et al. Stem Cells: Breakthroughs in Medicine and Therapeutics